Insights

Gathering insights about RLF…

Similar companies to RLF

RLF Tech Stack

Media & News

Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Study of RLF-OD032
RLF-OD032 demonstrated bioequivalence to KUVAN® Powder Study results support planned 505(b)(2) NDA submission in early 2026 GENEVA, SWITZERLAND / ACCESS Newswire / October 29, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced positive results from its pivotal bioequivalence clinical study evaluating RLF-OD032, Relief's innovative and highly concentrated liquid formulation of sapropterin dihydrochloride, for the treatment of phenylketonuria (PKU). The pivotal study achieved its primary pharmacokinetic endpoints, demonstrating that RLF-OD032 is bioequivalent to KUVAN ® Powder, the reference listed drug, as defined by the U.S. Food and Drug Administration.
Oct 29, 2025 | www.accessnewswire.com
Relief Therapeutics Publishes 2025 Half-Year Report
GENEVAD, SE / ACCESS Newswire / August 14, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced the publication of its 2025 half-year report and provided a corporate update. "Relief continued to make steady progress across our pipeline and corporate initiatives," said Dr. Raghuram Selvaraju, chairman of the board of directors.
Aug 14, 2025 | www.accessnewswire.com
Relief Therapeutics Advances Publication of 2025 Half-Year Report
GENEVA, SWITZERLAND / ACCESS Newswire / August 11, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced that it has advanced the publication date of its 2025 half-year report. Originally scheduled for release on August 27, 2025, the report will now be published on August 14, 2025, ahead of market opening.
Aug 11, 2025 | www.accessnewswire.com
Relief Therapeutics Announces Proposed Business Combination with NeuroX, Successor to MindMaze
NeuroX recently acquired the assets and operations of MindMaze, a world-renowned leader in evidence-based neurotherapeutic solutions for neurological diseases and brain disorders Business combination to create an expanded, SIX-listed, commercial-stage, AI-driven, scalable health tech company Binding term sheet signed; transaction subject to customary conditions and approvals Closing expected in Q4 2025 GENEVA, SWITZERLAND / ACCESS Newswire / July 29, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) ("Relief" or the "Company"), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced the execution of a binding term sheet for a proposed business combination with NeuroX Group SA ("NeuroX"), a privately held company that recently acquired the assets and operations of MindMaze - a recognized leader in digital neurotherapeutics and brain health technologies. The envisaged combination aims to create a publicly listed, AI-based therapeutics platform integrating software-delivered, disease-modifying clinical interventions with pharmacological treatments and a comprehensive brain health platform to improve the quality of life of patients, caregivers and families.
Jul 29, 2025 | www.accessnewswire.com
Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011
GENEVA, SWITZERLAND / ACCESS Newswire / June 20, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced that its initial request for Qualified Infectious Disease Product (QIDP) designation for RLF-TD011 for the treatment of epidermolysis bullosa (EB) was not granted by the U.S. Food and Drug Administration (FDA). The FDA determined that the investigational therapy does not currently meet the criteria for QIDP designation.
Jun 20, 2025 | www.accessnewswire.com
Relief Therapeutics Announces Results of Annual General Meeting
Shareholders approved all proposals by a large majority GENEVA, SWITZERLAND / ACCESS Newswire / June 12, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief Therapeutics, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced the results of its annual general meeting (AGM) of shareholders, held earlier today in Geneva. All proposed resolutions were approved by more than 85 percent of the represented votes.
Jun 12, 2025 | www.accessnewswire.com
Relief Therapeutics Receives FDA Rare Pediatric Disease Designation for RLF-TD011
GENEVA, SWITZERLAND / ACCESS Newswire / May 22, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation to RLF-TD011 for the treatment of epidermolysis bullosa (EB), a rare genetic skin disorder characterized by fragile skin and chronic wounds. The FDA had previously granted Orphan Drug Designation to RLF-TD011 for the same indication.
May 22, 2025 | www.accessnewswire.com

RLF's Email Address Formats

RLF uses at least 2 format(s):

RLF Email Formats	Example	Percentage
First_Last@rlfae.com	John_Doe@rlfae.com	75%
Last@rlfae.com	Doe@rlfae.com	15%
FirstLast@rlfae.com	JohnDoe@rlfae.com	10%

Frequently Asked Questions

What is RLF's phone number?

You can contact RLF's main corporate office by phone at

+1-407-730-****

. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is RLF's stock symbol?

RLF is a publicly traded company; the company's stock symbol is RLFTY.

What is RLF's official website and social media links?

RLF's official website is rlfaei.com and has social profiles on LinkedIn.

What is RLF's NAICS code?

RLF's NAICS code is 54131 - Architectural Services.

How many employees does RLF have currently?

As of December 2025, RLF has approximately 218 employees across 3 continents, including North AmericaEuropeAsia. Key team members include Chief Strategy Officer (cso): R. S.Chief Financial Officer: B. J.Chief Financial Officer: S. H.. Explore RLF's employee directory with LeadIQ.

What industry does RLF belong to?

RLF operates in the Architecture and Planning industry.

What is RLF's email format?

RLF's email format typically follows the pattern of First_Last@rlfae.com. Find more RLF email formats with LeadIQ.

When was RLF founded?

RLF was founded in 1935.

RLF

Q: What is RLF's official website and social media links?

RLF's official website is rlfaei.com. RLF has social profiles on LinkedIn.

Q: How many employees does RLF have currently?

RLF has approximately 218 employees.

Architecture and PlanningFlorida, United States201-500 Employees

Rogers, Lovelock and Fritz, Inc. (RLF) was founded in 1935 and is one of the oldest practicing design firms in the state of Florida. Nationally recognized for architecture, engineering and interior design services, the Central Florida firm has completed projects in 37 states, 25 countries and five continents, focusing on federal, healthcare, education, eldercare and community work. RLF’s staff of 130+ professionals provide individual client-focused services to create contemporary, innovative designs that make a positive impact on the communities they serve.